![Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older Than 70 Years; Survival Benefit at Considerable Morbidity and Mortality | Semantic Scholar Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older Than 70 Years; Survival Benefit at Considerable Morbidity and Mortality | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/56ee22a8d63831822cfb425a2debd97aae463554/4-Figure1-1.png)
Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older Than 70 Years; Survival Benefit at Considerable Morbidity and Mortality | Semantic Scholar
![Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older Than 70 Years; Survival Benefit at Considerable Morbidity and Mortality | Semantic Scholar Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older Than 70 Years; Survival Benefit at Considerable Morbidity and Mortality | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/56ee22a8d63831822cfb425a2debd97aae463554/3-Table2-1.png)
Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older Than 70 Years; Survival Benefit at Considerable Morbidity and Mortality | Semantic Scholar
Ioannis C Kotsopoulos MD, MPhil, PhD - Honorary Associate Professor, Women's Cancer, Institute for Women's Health - UCL | LinkedIn
John Spiliotis MD, PhD - Surgeon Oncologist, Director and Chairman Peritoneal Surface Oncology - Athens Medical Group & European Interbalkan Medical Center | LinkedIn
Ioannis C Kotsopoulos MD, MPhil, PhD - Honorary Associate Professor, Women's Cancer, Institute for Women's Health - UCL | LinkedIn
![CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: The small-bowel PCI score as a predictor of survival CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: The small-bowel PCI score as a predictor of survival](https://www.degruyter.com/document/doi/10.1515/pp-2019-0018/asset/graphic/j_pp-2019-0018_fig_002.jpg)
CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: The small-bowel PCI score as a predictor of survival
![Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). | Semantic Scholar Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/98ef6a65ce8d2447790ed07b3bf016a5e067d2b4/3-Table1-1.png)
Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). | Semantic Scholar
![PDF] Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. | Semantic Scholar PDF] Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/54d0d3bd7177b739fd4117b3a0613d2f1fc3fa0f/7-Figure3-1.png)
PDF] Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. | Semantic Scholar
![Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older Than 70 Years; Survival Benefit at Considerable Morbidity and Mortality | Semantic Scholar Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older Than 70 Years; Survival Benefit at Considerable Morbidity and Mortality | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/56ee22a8d63831822cfb425a2debd97aae463554/4-Figure3-1.png)